Last updated: February 24, 2026
What is NDC 75834-0209?
NDC 75834-0209 is the identifier for a specific pharmaceutical product. Based on available data, this NDC corresponds to Rucaparib (brand name: Rubraca), an oral PARP inhibitor approved for certain ovarian and prostate cancers.
Market Overview
Indications and Prescriptions
- Approved indications include maintenance treatment of recurrent ovarian cancer with homologous recombination deficiency (HRD) and treatment of metastatic castration-resistant prostate cancer.
- Market penetration correlates with the prevalence of these cancers, estimated globally at 300,000 ovarian and 250,000 prostate cases annually [1].
Competitive Landscape
- Main competitors include Olaparib (Lynparza), Niraparib (Zejula), and Talazoparib (Talzenna).
- These drugs hold a combined market share exceeding 75% in PARP inhibitors.
Adoption Factors
- Approval for multiple indications expands potential patient base.
- Usage is limited by reimbursement policies and physician familiarity.
Pricing Context
- PARP inhibitors typically priced between $8,000 to $16,000 per month.
- Rucaparib's average wholesale price (AWP) stands approximately at $12,500 per month [2].
Price Projections
Current Price Benchmarks
- Rucaparib (NDC 75834-0209): Approximate retail price ranges from $11,500 to $13,000 per month depending on pharmacy and insurance coverage.
- Competitive drugs:
- Olaparib: ~$13,000/month.
- Niraparib: ~$8,500/month.
- Talazoparib: ~$14,000/month.
Future Price Trends
- Patent expiry for Rucaparib is anticipated around 2030, potentially leading to generic entrants.
- Historically, similar oncology drugs see a 20-40% price reduction within five years of generic launch.
| Year |
Estimated Price Range |
Key Factors |
| 2023 |
$11,500–$13,000 |
Current exclusivity, no generic competition |
| 2025 |
$9,000–$11,500 |
Possible biosimilar/generic entry preparation |
| 2030 |
<$5,000 |
Likely generic market penetration |
Market Dynamics Impacting Price
- Increasing patent challenges or patent extensions.
- Reimbursement policy changes favoring cost-effective alternatives.
- Expanded indication approvals could sustain higher prices through increased use.
Market Size Projections
Sales Revenue Estimates
- Expected to reach approximately $1.2 billion globally by 2025, driven by increased adoption in ovarian and prostate indications.
- Growth rate estimated at 10-12% annually over the next three years.
Key Drivers
- Growing prevalence of ovarian and prostate cancers.
- Adoption of PARP inhibitors as standard care.
- Expanded patient access to genetic testing enabling targeted therapy.
Challenges
- Price sensitivity and payer restrictions limit sales growth.
- Competition from lower-cost biosimilars or new entrants.
- Evolving treatment guidelines.
Regulatory and Market Entry Considerations
- Patents protect Rucaparib until 2030, with potential extensions.
- Launching generics pre-2030 could substantially alter pricing.
- Pricing and formulary access vary across regions, impacting revenue potential.
Key Takeaways
- NDC 75834-0209 corresponds to Rucaparib, a PARP inhibitor with high current pricing (~$12,000/month).
- The drug faces competition from Olaparib, Niraparib, and Talazoparib, whose pricing ranges from $8,500 to over $14,000 monthly.
- Market size is projected to grow to over $1 billion globally by 2025, driven by increased indications and adoption.
- Price declines forecasted post-patent expiry, with potential generic entry causing a 50-70% drop within five years of launch.
- Pricing strategies should factor in competition, patent timeline, reimbursement policies, and evolving clinical guidelines.
FAQs
1. What is the primary use of NDC 75834-0209?
It is used for treating specific ovarian and prostate cancers with a PARP inhibitor mechanism.
2. When might generic versions of Rucaparib become available?
Potentially around 2030, depending on patent challenges or extensions.
3. How does the price of Rucaparib compare with competitors?
It is among the higher-priced PARP inhibitors at approximately $12,500/month, with competitors ranging from about $8,500 to over $14,000.
4. What factors could influence a price drop for Rucaparib?
Patent expiration, biosimilar entries, changes in reimbursement policies, and increased market competition.
5. How significant is the market for PARP inhibitors?
Expected to reach over $1 billion globally by 2025, driven by increasing cancer prevalence and expanded indications.
References
[1] American Cancer Society. Cancer Facts & Figures 2022.
[2] IQVIA. Price data for oncology drugs, 2023.
